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necessary for a new era of patient-centred




Background: The public and healthcare workers have a high expectation of animal research which they perceive
as necessary to predict the safety and efficacy of drugs before testing in clinical trials. However, the expectation is
not always realised and there is evidence that the research often fails to stand up to scientific scrutiny and its
'predictive value' is either weak or absent.
Discussion: Problems with the use of animals as models of humans arise from a variety of biases and systemic
failures including: 1) bias and poor practice in research methodology and data analysis; 2) lack of transparency
in scientific assessment and regulation of the research; 3) long-term denial of weaknesses in cross-species
translation; 4) profit-driven motives overriding patient interests; 5) lack of accountability of expenditure on
animal research; 6) reductionist-materialism in science which tends to dictate scientific inquiry and control the
direction of funding in biomedical research.
Summary: Bias in animal research needs to be addressed before medical research and healthcare decision-making
can be more evidence-based. Research funding may be misdirected on studying 'disease mechanisms' in animals that
cannot be replicated outside tightly controlled laboratory conditions, and without sufficient critical evaluation animal
research may divert attention away from avenues of research that hold promise for human health. The potential for
harm to patients and trial volunteers from reliance on biased animal data1 requires measures to improve its conduct,
regulation and analysis. This article draws attention to a few of the many forms of bias in animal research that have
come to light in the last decade and offers a strategy incorporating ten recommendations stated at the end of each
section on bias. The proposals need development through open debate and subsequent rigorous implementation so
that reviewers may determine the value of animal research to human health. The 10Rs + are protected by a Creative
Commons Attribution 3.0 Unported License and therefore may be 'shared, remixed or built on, even commercially, so
long as attributed by giving appropriate credit with a link to the license, and indicate if changes were made.’
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Introduction
The concept of using animals as surrogate models for
humans relies on the conjecture that animal species
predict the human outcome. However, bias and conflict
of interest make it difficult to confirm the hypothesis
and evidence suggests that animal studies are inconsist-
ent in translation to human health; [1, 2] rather than
delivering reliable answers to research questions they
are often overinterpreted [3].
While there remains a lack of scientific robustness
in animal research and failure to sufficiently screen
for poor quality research, this situation will nega-
tively impact on our healthcare system. It might then
be unreasonable to expect continued public and pro-
fessional support for animal research if reviewers are
unable to determine either the scientific or ethical
quality of the studies.
Discussion
Various forms of bias are found throughout animal
research; in the design, reporting, publication,
analysis, regulation, funding and validation of animal
models. Failure to adequately correct for bias by utilis-
ing the best available research methods is evidenced
by misleading results [4], which have needlessly in-
volved thousands of participants in clinical trials [5–9]
and wasted funding and resources [10].
In 2004 the US FDA produced a white paper that
looked at the disconnect between increased expend-
iture in R&D and the high attrition (drop-out) rate
in drug discovery [11]. The report was critical of
pre-clinical animal models and called for better
models or better ways of predicting the outcome of
drug trials in patients. A decade later, in spite of ex-
tensive funding for the development and improve-
ment of animal models, [12, 13] the attrition rate has
not fallen and it is estimated that the likelihood of a
drug successfully passing Phase III is 50 %, and that
the overall attrition rate of late-stage drug develop-
ment is unsustainable [14]. Only 11 % of medical
compounds are approved for use following years of
research and development [15, 16].
The Lancet published a review in 2009 of the pro-
duction and reporting of biomedical research which
calculated 85 % of basic and clinical research is
wasted because of inadequate or inappropriate de-
sign, non-publication and poor reporting [17] result-
ing in an estimated global annual loss of over $100b
research funding [18]. The review also found that
only 10 % of government and charitable investment
in biomedical research in the UK was for treatment
evaluation while over two thirds was directed to-
wards basic research. The authors reasoned that
waste is largely preventable if:
 Existing research is reviewed and analysed using
high quality methods prior to funding more
research, and
 Research questions are designed to be of relevance
to patients and their clinicians.
Bias in design
Good medical research begins with asking research
questions responsive to the needs of patients and set in
the context of existing research. In their book ‘Testing
Treatments: Better Research for Better Healthcare’, the
authors say that most of the global funding of medical
research goes into laboratory and animal studies rather
than research that is likely to have more relevance to pa-
tients [19]. In 2004 the James Lind Alliance (JLA) was
formed with the aim of addressing this issue by generat-
ing research questions in favour of patient priorities and
interests over those of researchers and industry [20].
It would be expected that animal studies are always
carried out for sound scientific reasons but prestige,
economy and convenience may influence decisions
[21]. Publication in high impact factor journals is how
scientists are now rated, and in a recent survey that
looked at the convergence and divergence among clin-
ical and basic scientists the authors found that basic
scientists lacked involvement in the outcome of their
research and how it translated to patients. Personal
motivations came from scientific discovery rather than
application, and the main interest was studying
biological mechanisms in favour of research with little
financial gain [22].
A large part of medical research is narrowly focused
on drug development utilising the animal model in cel-
lular and molecular biology and genetic research [23].
The discovery of how to genetically modify mice has
produced a high percent of research using genetically
altered (GA) (usually rodent) animal models. Labora-
tory mice are used in animal studies disproportionately
more (95 % according to the US Foundation for Bio-
medical Research) than any other animal species. This
may be more for convenience than scientific consider-
ation but is now regarded as the norm. Mice are small,
docile, easily handled, housed and maintained and they
adapt quickly to new surroundings. Their reproduction
rate is fast and lifespan brief, allowing for generations
of mice to be studied in a short time-frame.
The research portfolio of the US National Institute of
Health (NIH) is a notable example of how research pri-
orities are weighted towards molecular and cellular
biology and gene research based on animal studies [24].
But although it is known that patients respond to drugs
differently according to genetic make-up, and that this
can be a reason why drugs fail in some patients and not
in others, pharmacogenomic animal models are causing
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difficulties with establishing appropriate predictive
models for the research [25] which has not been with-
out harm to patients and waste of research [26, 27].
Patients have their own treatment choices and prefer-
ences, which may not always include medication [28]. For
instance, the refugee and immigrant sections of the popu-
lation are high users of ethnic and traditional non-drug in-
terventions and the JLA have found that some patients
prefer coping strategies, nutrition, physiotherapy, surgery,
complementary medicine and other under-researched op-
tions rather than drug therapy [20] and the Cochrane De-
pression, Anxiety and Neurosis Review Group found
that exercise for depression is of equal efficacy to that of
medication [29], and yet little funding goes into research-
ing this intervention compared with funding drugs for
depression.
Recommendation (1) RESPOND to patients' needs by
asking research questions of relevance to patients and
their priorities.
Bias from irreproducibility and research misconduct
The attrition rate in drug discovery is reflected in the
many failures of human trials at clinical research Phases
II and III [14, 30]. This loss suggests that pre-clinical
animal trials may not always have the necessary capacity
to forecast the human response to drug therapy and
toxicological studies. The Director of the NIH cautions
that a high percentage of animal research may not be
relevant to the human situation (Collins) [31], and it is
estimated that 80-85 % of drugs effective in mice are in-
effective in humans and more than 30 % of drugs pass-
ing animal tests for safety show toxicity in human trials
(Geerts) [31]. The average rate of translation for animal
models of cancer is less than 8 % [32].
Pharmaceutical companies are under extreme pressure
from shareholders to raise share value, and investors are
becoming increasingly aware of the irreproducibility of ani-
mal studies. As a result the NIH recently announced an
initiative [3] to improve the quality of preclinical research,
prompted by concerns of investors and some sections of
the scientific community. Early-stage biotech venture cap-
italists have known for years that animal research is un-
reliable, but it is only recently that they have been
publicly involved in addressing the issue for their own
interests [33, 34].
A survey on data reproducibility in cancer studies re-
ported that some pre-clinical investigators knowingly use
unreliable data resulting in flawed research, which they
then pressure support staff to publish [4]. This author is
informed by a researcher using animals that they would
rather remain silent about the 'pervasive flaws' in their
field of animal research than report them. (Personal com-
munication undisclosed for protection of researcher).
Other acts of misconduct take place where basic
researchers collude with the pharmaceutical industry to
market drugs by accepting 'gifts' in various forms, in re-
turn for favours such as acknowledging the sponsor in
their reports, providing pre-publication reviews of articles
traceable to the gift, ghost-writing and ghost-management
of publications, reporting unwarranted efficacy of drugs,
under-reporting unfavourable results and selectively pre-
senting posters and abstracts at scientific meetings [35].
Toxicologists have continued for decades to ignore gen-
etic variation when selecting animal models even though
to do so leads to unreliable results [36] and using too few
animals in the design of experiments can be as wasteful as
using too many because the research becomes 'under-
powered' and consequently invalid leading to unrepeatable
work and avoidable repetition of research. It was only re-
cently in 2012 that industry realised the full impact of irre-
producibility when it conducted a study that found that 47
out of 53 cancer studies published in top tier jour-
nals could not be replicated and yet were published
as 'landmark' results. The author of the study con-
cluded, 'Although hundreds of thousands of research pa-
pers are published annually, too few clinical successes
have been produced given the public investment of signifi-
cant financial resources. We need a system that will facili-
tate a transparent discovery process that frequently and
consistently leads to significant patient benefit' [37].
Recommendation (2) REPLICATE animal studies inde-
pendently using scientific evidence-based methods and
standards prior to publication. Address research miscon-
duct and protect whistle-blowers.
Bias from lack of registration
Registration of animal trials is as necessary as it is for
clinical trials [38]. Reviewers need to monitor the claims
made in the research proposal against the published re-
sults in the same way as clinical trials. This cannot be
done unless the protocol and aims of the research are
recorded beforehand. The first time it was noted that
prospective registration of animal studies is not in prac-
tice was in the BMJ in 2002 [39], but in spite of repeated
calls there are no registers. This failure leaves animal
studies vulnerable to researchers changing the endpoints
and details of the research after it has started and allows
them not to publish unfavourable or negative results of
their research. In 2013 the Centre for Reviews and Dis-
semination (CRD) gave a presentation ‘Registration of
experimental studies and systematic reviews’ [40], which
highlighted the principles of registration for both animal
and human studies:
 Availability of evidence to inform health care
decisions
 Avoidance of publication bias and selective reporting
bias
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 Requirement of the Declaration of Helsinki
 Avoidance of unnecessary duplication
 Identification of gaps in research
 Facilitation of recruitment
 Promotion of collaboration
 Early identification of potential problems
Recommendation (3) REGISTER all animal trials pro-
spectively on an open global register.
Bias from poor reporting
Reporting and accounting for details of an animal trial
in a study protocol is essential in order to avoid publica-
tion bias, assist replication and justify the research.
Methods of statistical analysis used, sample sizes, inclu-
sion/exclusion criteria, methods of randomisation, blind-
ing, gender, strain, species selection, and age of
animals all need to be reported. Al-Shahi Salman and
colleagues refer to systematic reviews (SRs) that have
shown fewer than 2 % of animal studies explained the
basis for their sample size calculations [41].
Variables frequently confound research and need to be
identified, measured and controlled to avoid damaging
the internal validity of the study. For example, research
results have been skewed by noise, infection, infesta-
tions, microorganisms and pathogens [42–44] and envir-
onmental temperature affected the results of cancer
research [45]. More recently it was found that human
gender disparity heightened stress levels in laboratory
rodents affecting their analgesic responses [46]. Another
study using only males of the selected animal models
confounded the research. See [Table 1.] for a more com-
prehensive list of variables.
Several guidelines have been issued recently to improve
poor reporting. In 2010 the ‘Animal Research: Reporting
of In Vivo Experiments’ (ARRIVE) [47] was published,
and then in 2011 the Gold Standard Publication Checklist
(GSPC) improved and further elucidated the ARRIVE
reporting requirements [48]. Following these, in 2013,
Nature Journal issued it's own checklist to encourage au-
thors to report details of their research precisely and
methodically with more statistical information, setting
higher standards for the research they publish and which
will influence other journals to do the same.
The ARRIVE guidelines have been endorsed by over
300 major journals since they were first published,
however, there has been some criticism that they are
not adhered to [49], that they do not go far enough,
and that animal trials should be carried out to the same
standards as those set for clinical trials with greater
attention paid to reducing bias [50]. Although the
guidelines list suggestions for improved reporting, there
is currently no requirement to comprehensively and
uniformly identify and report all details of research in a
study protocol. As a consequence there is a noticeable
lack of consistency of reporting in journals making it
difficult for reviewers and other readers of research pa-
pers to make fair assessments.
Recommendation (4) REPORT all details of the re-
search in a well written protocol (plan of the research).
Journals to improve on and enforce adherence to guide-
lines for animal research.
Bias from non-publication
A survey on publication bias in laboratory animal re-
search found that researchers in academia estimated
only 50 % of animal research is published while re-
searchers in industry estimated only 10 % is published
[51]. In 2010 a report by the Health Technology Assess-
ment (HTA), looking at publication and related biases in
medical research [52], concluded that publication bias
could be one of several explanations for the lack of
translation from basic research to the clinical situation.
In animal studies of neurological disease, for instance,
reviewers found excess significance bias and summarised
that only eight of the 160 evaluated treatments should
have been tested in humans [53].
In June 2013 Doshi and colleagues published a pro-
posal for restoring invisible and abandoned clinical trials.
The project known as RIAT (Restoring Invisible and
Abandoned Trials) aims to publish or re-publish all clin-
ical 'grey literature', but the same improvement should
be applied to animal studies so that reviewers can trace
the research back to the original research, to get a
complete picture of all the results and processes that
have led to the clinical studies.
Recommendation (5) RECORD (publish) the results of
all animal trials in science journals regardless of whether
the outcomes are positive, negative or null.
Bias from lack of systematic review
It is estimated that there are over 7 million published
animal studies of which over 5 million are on PubMed
[54] and yet only 91 SRs of animal studies were pub-
lished during the years 2005 to 2012 inclusive (on any
topic). In only 48 of the SR's was a risk of bias or quality
assessment performed, a necessary step in SR method-
ology. The quality of the primary studies was low, and of
these only approximately 20 % checked several issues for
the risk of bias and internal and external validity [55].
In 2002 a SR in the BMJ on fluid resuscitation was
perhaps the first paper to raise the question of why SRs
of animal studies were not prevalent [39], and in the
same year the Lancet published a paper which called for
the requirement of SRs of all relevant animal and human
studies before proceeding with clinical trials [56].
The Nuffield Council on Bioethics produced a report in
2005 which directed a recommendation to the leading
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funders of animal research, the pharmaceutical industry
and animal protection groups in the UK to fund SRs of
animal studies "to evaluate more fully the predictability
and transferability of animal models" [57]. Following that
in 2007 the HTA commissioned a pilot study to assess the
extent of concordance between animal and human studies
of treatments and determine whether SRs of animal trials
would help to answer questions about their relevance to
human treatments and interventions. The study
found some discordance between the animal and human
studies and confirmed that SRs are valuable, but it also
found insufficient evidence to quantitatively determine the
generalisability of animal research to human medicine and
recommended that funding should go into this area of re-
search [58].
There has been a small increase in the number of SRs
of animal trials since these reports, but they remain
scarce in comparison to those of clinical trials [59] and
almost non-existent in comparison to the amount of
published animal literature.
The study of animal models of stroke is probably the
most reviewed field of animal studies for relevance to
clinical research, beginning in 2001 when Horn and col-
leagues were arguably the first researchers to conduct a
SR of animal studies. Their review of nimodipine [5]
found the methodological quality of the animal studies
was poor, and that only 50 % of the studies were in
favour of the intervention with no convincing evidence
to start clinical trials which had involved thousands of
patients. The animal trials of nimodipine continued for
over 15 years after clinical trials had started, and some
animal and clinical trials ran concurrently, which the
Table 1 Confounding variables in the design and reporting of
animal study protocols (list not exhaustive)
Ages of animals
Animals added to replace drop-outs
Bedding type/quantity
Blinding (i.e. blinding the investigators and staff to allocation)
Breeding
Cage position on shelving
Cage size/material
Circadian rythms
Cleaning (chemicals, methods and manual or automated cage washing)
Colony size
Co-morbidity
Dosing style and route
Enrichment methods and practices
Environmental (other)
Exercise (methods, equipment, timing, amount, locations)
Feeding (equipment, methods, timing, amount)
Feeds (type)
Frequency of intervention
Gender (male and/or female included)









Methods used to conceal allocation sequence
Methods used to generate allocation sequence
Model type (induced, spontaneous, transgenic, negative, orphan, or
other)
Noise (background and foreground)
Nutritional deficiencies due to lack of normal living conditions
Odours (e.g. perfumes worn by technicians, laundry and cleaning
products and medications)
Polypharmacy (whether accounted for to mimic target population -
humans)
Randomisation of animals (details of methods used)
Recording methods (manual, electronic)
Research methods
Sample size estimation (whether computed and statistical method of
computation)
Sampling of style and route
Sources of animals (e.g. same model may vary depending on supplier
used)
Table 1 Confounding variables in the design and reporting of
animal study protocols (list not exhaustive) (Continued)
Species
Staff changes and variation of routines
Staff numbers and attitudes
Statistics (full information on statistical methods used)
Strain








Water and watering methods
Weight of animals
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reviewers found surprising. Other SRs of stroke research
found bias and methodological weaknesses, and that al-
most no new drug interventions translated to the clinic
following decades of animal and clinical trials [60].
Researchers are more likely to receive funding to
publish new animal studies and develop more animal
models [19, 61] than to critically appraise existing stud-
ies and models. Even while debate is underway amongst
researchers about how or whether to take animal data
to the clinic, the clinical trials may still be carried out
[32]. Participants in Phase I trials should be adequately
informed before signing consent forms, [62] and if SRs
have not been conducted, or are not available, the
advice is not to enter the trial [19].
Recommendation (6) REVIEW animal trials using sys-
tematic review.
Bias in the regulation of animal research
In an article in Nature in 2004, calling for a more
evidence-based regulatory system in the drug industry, the
author was critical of the existing system saying that many
regulations are based on expert opinion rather than evi-
dence and that there needs to be quantitative assessment
of the predictive value of preclinical studies [63]. A decade
later, in an article in Drug Discovery Today, an industry-
based researcher (preclinical and clinical) commented that
the regulatory agencies require preclinical investigational
new drug packages (applications) to contain efficacy and
other data from studies that use animal models even
where they are known to be unpredictive [64].
The regulation of animal research in the UK is guided
by three principles known as the 3Rs (refine, reduce
and/or replace experiments using animals), with the
intention of contributing to the welfare of laboratory an-
imals. They were first published in England by animal
researchers Russell and Burch in 1959, a time when ani-
mals were mainly used for screening chemicals for bio-
logical activity [65].
The 3Rs rest on the assertion that research questions
about humans can be answered by studying animals.
The first two principles, 'refinement' and 'reduction',
fully support this notion and have little bearing on scien-
tific questioning of animal models. The third principle,
known as 'replace', supports the notion whereby animal
models are regarded as the 'gold standard, and all non-
animal research models are classified as 'alternatives',
which must be validated against animal models before
they can 'replace' the animal model in practice. Al-
though there is little agreement between companies
and academia about the methods of validation of ani-
mal models, the non-animal technologies are generally
regarded as inferior by regulators even where re-
searchers develop effective human-based models that
are highly predictive [64, 66].
The 'harm-benefit assessment' (harm to laboratory ani-
mals in terms of welfare – benefit in terms of human
health) is the earliest part of the approval process of ani-
mal research. This assessment is carried out in the UK
by the Animals in Science Regulation Unit (ASRU), a
body of twenty three inspectors, mainly veterinarians.
They inspect the 180 research establishments through-
out the country to see that they comply with animal wel-
fare requirements [67]. Their remaining time involves
assessing and authorising each animal research applica-
tion using the 'harm-benefit assessment'. However, the
assessment is neither open nor transparent and relies on
the individual expert opinion of the inspector.
Details of how many applications inspectors approve
or turn down and the reasons why are not disclosed, but
it has been reported that an application may be turned
down by one inspector in one part of the country while
the same project is approved in another [68]. From the
little information available about the work of inspectors
and how it is regulated, it would appear that the 'harm-
benefit assessment' is mainly concerned with assessing
animal welfare and compliance with the 3Rs.
Definition of the 'benefits' part of the analysis is quite
generalised in the guidelines [69], and there is no re-
quirement to carry out a SR before making the applica-
tion. Instead, a set of general questions is asked such as
"Clarify the current state of knowledge on which your
project intends to build" and "Is the work scientifically
sound?" The inspectors rely on the accuracy and honesty
of the answers given by the applicant on the forms.
Once an inspector has approved a project licence ap-
plication, it is passed to a local animal ethics committee
known as an Animal Welfare Ethical Review Board
(AWERB). Members are selected from the institution
where the research is taking place, often including the
researchers themselves. Concerns have been raised about
this practice and that animal researchers and AWERB
members are not usually trained in research method-
ology and statistical analysis [70]. Some Universities ac-
tively reject potential panel members with appropriate
expertise and less subjective involvement (personal com-
munication undisclosed for protection of reviewer). This
is quite common and may affect the legitimacy of the
approval process [71, 72].
Like the ASRU, the purpose of the AWERB is to weigh
the harm-benefits of the research project. However, like
the assessments of the ASRU, the review process is not
transparent or open to inspection and consequently there
is no connection between the approval of animal research
and the published results. The expertise and aims of both
the ASRU and the AWERB are orientated towards animal
welfare compliance, and while ethical reviews will contain
detailed information about animal procedures pertaining
to the 3Rs there is limited scientific information. Since
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there is no publication of the review it is impossible to
monitor its effectiveness. A group of European researchers
studying the ethical review process [73] says that this
could be rectified by the following actions:
 Journals to require the complete legal reference
document including the name of the ethical entity
that gave authorisation.
 Make the ethical review approval records available
(without disclosing individual researchers' identities
or personal details) either by publication as online
supplementary material in journals or on a separate
database.
 Prospectively register all animal trials with an
identifying number.
There is mounting criticism in the US that the commit-
tees equivalent to AWERBs, known as the Institutional
Animal Care and Use Committees (IACUCs), approve
nearly every animal project that they review. As a conse-
quence physician-scientists are turning away from human-
based research in favour of animal research for which they
can expect ease of approval and funding. In contrast, the
US Institutional Review Board (IRB) that reviews clinical
projects is criticised for creating numerous hurdles in the
approval process, increasing the trend for physician-
scientists to turn towards animal research [74].
A Social Science and Medicine study in 2010 on the
use of rodent and GM mice models of carcinogenic risk
assessment revealed how industry drives the science
underpinning safety testing of drugs by manipulation of
the validation of animal models for its own ends, and
how the regulatory bodies collude with industry until
there is a crisis and then the regulations are tightened
only to protect the reputation of the regulators. After-
wards regulation drifts back to accommodate industrial
motives [75]. The study raises questions about the cred-
ibility of the validation of animal models, how profit-
making influences animal testing and how industry is
deeply embedded in the regulatory process.
Recommendation (7) REGULATE animal research
using evidence-based methods and overhaul the regula-
tory system.
Bias in the hypothesis and quantitative appraisal of
animal research
The latest student guidance notes on the selection of ani-
mal models state 'the rationale behind extrapolating results
to other species is based on the extensive homology and
evolutionary similarity between morphological structures
and physiological processes among different animal species
and between animals and humans'. But despite decades of
research relying on this rationale, expounded by Calabrese
in 1983 [76], the hypothesis has not been verified [77].
The validation process raises questions about whether
animal models can be regarded as a reliable scientific
tool [78]. Non-animal technologies undergo rigorous
and lengthy (years) testing against a 'gold standard' ani-
mal model before they are approved. Even when it is
completed the adoption of the new model or method
may be overridden by the regulatory bodies, and non-
predictive or irrelevant animal models used [64, 66] But
animal models have not undergone validation to the
same extent or to the same exacting standards [79].
Where it is carried out, validation is limited and uses
disparate methods of assessment. The inaccessibility of
raw animal and clinical data, lack of consensus on devel-
opment and validation of animal models, and no common
agreement of testing methods between companies and
academia, can result in an inconsistent and flawed statis-
tical and analytical validation [80–84].
Bennani lists several human diseases for which animal




 Central nervous system (CNS)
 Other neurological (e.g. pain)
 HIV
 Hepatitis C (HCV) infections
For some other conditions he says animal models are
'more reliable' such as influenza, bacterial and fungal
infections, measuring CVD and LDL and simple blood
chemistry read-outs such as glucose or cholesterol
[64]. However, animals rarely characterise a human
condition exactly. No animal models of influenza, for
instance, mimic human influenza and researchers
model for the virus in several different species in the
hope that gathering a collection of data may be useful
in drug discovery [85, 86].
A workshop on animal models of CNS reported in
2013 that there are no animal models that predict hu-
man diseases or disorders [87]. The consensus was that
researchers could probably only hope to model disease
mechanisms or phenotypes, and that animal models
should not be called models of a particular human con-
dition or disease but instead labelled for the hypotheses
or mechanisms studied.
In a recent paper detailing how to use meta-analysis as
a solution to translational problems in animal research,
the authors claim that animal studies are not only 'cru-
cial' to understanding disease mechanisms but also for
testing drugs for toxicity and efficacy [88]. They say that
success in translating findings from animal studies to
humans depends on understanding sources of heterogen-
eity in the published studies. While their paper is a useful
Green BMC Medical Ethics  (2015) 16:53 Page 7 of 14
and practical guide to systematically analysing animal data
from the study of disease mechanisms in animals, their as-
sertion that the use of animal studies is 'crucial' for testing
drugs for toxicity and efficacy is challenged by evidence
from academia [59], industry [64, 89] and toxicology [90]
and overlooks four problems as discussed in a paper on
extrapolation and translation of research [91]. The
problems are summarised as follows:
 Our understanding of mechanisms is often
incomplete.
 Knowledge of mechanisms is not always applicable
outside the tightly controlled laboratory conditions
in which it is gained.
 Mechanisms can behave paradoxically.
 Mechanistic knowledge faces the problem of the
'extrapolator's circle'.2
The authors warn that studying mechanisms in the
study population (animals) in order to translate the find-
ing to the target population (humans) is only valid in ex-
ceptional cases and that we need more reliable solutions.
The response to address difficulties with the transla-
tion of animal experiments to the clinic has mainly been
'build better animal models', and increasing numbers are
produced. JAXmice® alone stocks tens of thousands of
types of strains of mouse models to choose from [92],
and attempts at creating better models have resulted in
what the industry labels 'humanised' mice models (mice
carrying human genes, cells, tissues and/or organs), ani-
mals with 'sterile' immune systems, transgenic animal
models (Tg) and chimeric models (animals engineered with
human material inserted), such as the NOD.Cg-Rag1tm1-
Mom Il2rgtm1Wjl Tg(HLADRA,HLA-DRB1*0401)39-
2Kito/ScasJ strain [93].
For a scientific method of testing to be valid, it should
possess what is termed 'predictive value' with 'demon-
strable evidential weight'. A detailed discussion on the pre-
dictive value of animal tests can be found in the Journal of
the Royal Society of Medicine [94], but it is only recently
that a thorough statistical evaluation of toxicological and
pharmacokinetic animal data has been carried out. This
was made possible by the (unusual) cooperation from in-
dustry when it released a large canine dataset. The analysis
found no evidential weight to support canine data to pre-
dict efficacy and toxicology of medical compounds in clin-
ical trials [80].
In fields of scientific research such as aeronautics,
space science, computer science or engineering, it is
generally accepted as important to revisit failed pro-
jects, reappraise the studies and learn from mistakes. A
lack of predictive value in a research model would be
acknowledged as a failure of the model. But although a
significant amount of animal research does not
produce hoped-for results, little is critically appraised
by SR and meta-analysis [95]. This wasteful approach
of abandoning unsuccessful research and starting again
without re-evaluating the failed work would be consid-
ered inadmissible in most science-based industries.
A study in 2012 by van Meer and colleagues found
that animal data were not predictive for detecting ser-
ious post-marketing adverse drug reactions in patients
and should not be included in prospective pharmacov-
igilance studies [77]. Instead, the researchers have de-
veloped a method which, they say, can be adapted to
evaluate all drugs on the market as well as those still in
development to assess the predictive value of animal
studies. They summarise the situation and what needs
to be done:
'The adoption of the precautionary principle by the
regulatory authorities and the relative ease with which
this burden of proof is accepted by the pharmaceutical
industry - without attempts to improve the current
paradigm - has created a stalemate in which animal
studies, predictive or not, continue to exist with little
room for innovation. Stakeholders in industry,
academia and regulatory agencies, need to critically
assess animal studies and discuss their predictive value
in all earnestness and with the scientific facts at hand.
From this, possibilities based on scientific facts may
develop which allow new technologies to be
implemented that predict the safety and efficacy of
therapeutics equal to or better than animal studies do.
A way forward would be for the pharmaceutical
industry to share clinical and laboratory data generated
at all stages of product development with collaborating
stakeholders, to enable a complete and transparent
analysis of the predictive value of animal studies for
drug development' [96].
Recommendation (8) REAPPRAISE the validity of the
hypothesis that animals make reliable models for
humans and that they possess predictive value.
Bias from lack of economic assessment
The production of animal models is a lucrative and com-
petitive business. It has been estimated that the UK
alone expended 4.02 million animal models in research
in 2013, of which over 3 million were mice. The mouse
model (mentioned above) costs $155.35 (£94) per mouse
at weaning age including shipping [97]. Some mouse
models, such as the AD (Alzheimer's Disease) mice cost
more, for example, the beta-amyloid transgenic mouse
comes in at over $500 (£303) each. The Jackson Labora-
tory Humanized CD34+ NSG mice are as much as
$1300 (£760) per mouse.
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Expensive price tags on animal models and associated
expenses indicate that animal research is a costly com-
ponent in the drug discovery process, and which is fur-
ther increased by high levels of customisation according
to the field studied. Animal models can be purchased
off-the-peg or customised from online stores where they
are sold on an industrial scale [98, 99], as are specialised
animal feeds and associated technical equipment
[98, 100]. For a list of potential cost factors in animal re-
search see [Table 2].
In 2003 a report by the Health Economics Research
Group (HERG) found that only 2 %-21 % of basic re-
search translated into clinical benefit for patients [101].
The authors had examined a publication from 1976 in
Table 2 Cost factors in animal research (list not exhaustive)
ACU/OCU staff members salaries
Administration and IT
Air filtration systems in the vivarium buildings
Anaesthetics
Analgesics
Animal health diagnostic services and equipment
Animal models (various)
Animal transfer stations (change stations)
Autoclaves
Automated cage washing equipment
Bedding (specialised types of bedding)
Bedding disposal stations and units
Biological work stations Blood analysis equipment
Bottle fill stations
Breeding imports and exports
Cage card holders (various for different size and types of cage)
Cage shelving
Caging and cage trolleys (various for different sizes and types of species)












Handling gloves and clothing (specialised according to species)
Heating and lighting equipment
High-efficiency particulate air filtration systems
Housing (specialised premises with airlock barriers between vivarium
rooms)
Husbandry facilities and equipment
Imaging Xray and CAT
Importation & Exportation costs
Incubators
Inhalation equipment
Intensive care units (ICU)





Table 2 Cost factors in animal research (list not exhaustive)
(Continued)
Necropsy tables (various sizes)
Plethysmometer
Power lift
Protective clothing for automated cage cleaning
Respirators
Restraint frames and jackets (customised according to species)




Specific pathogen free cage housing rooms (in addition to regular ones)
Staff Training
Stationery and recording equipment
Sterile and germfree transportation equipment
Sterilisers
Surgical cleaning and scrub equipment and products
Surgical equipment (i.e. cauterisation, homeothermic, stereotaxic,
lighting)
Surgical specialised workwear
Surgical, blood and crematory waste services and equipment
Syringe pumps
Transportation (International & Domestic)
Ultraviolet light-treated deionized water lines
Urine analysis
Urine and feaces ammonia levels monitoring equipment
Vacuum units
Ventilators
Watering equipment (different sizes and types for different species)
Water (for animal drinking, cage cleaning and vivarium and surgical
cleaning)
Weighing and scales equipment (different sizes for different species)
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which it was claimed that 62 % of basic research articles
were judged essential for later clinical advances [102],
and as a direct result of that publication, funding has
been directed in favour of basic research. Although it is
now understood that applied clinical research has
greater benefit for patients [103–105], proportional
funding allocation has yet to accord with the evidence.
A regular and transparent account of spending on ani-
mal research does not appear to be carried out anywhere.
However, in 2009 it was estimated that approximately £8
billion (€10b /US$14 billion) was spent on animal experi-
mentation worldwide of which £1.7 billion (€2 billion/
US$2.8 billion) was for toxicological studies [106]. In
2009/10 the Medical Research Council (MRC), a major
funder of animal research in the UK, published that it
spent 30 % (£227 m) of its annual research budget on
research involving animal species.
DiMasi and colleagues have carried out several eco-
nomic assessments to evaluate the costs of drug devel-
opment and some included basic research costs. Their
estimation of preclinical cost per approved new drug in
2000 was $335m, but they found that the way in which
companies reported the costs of basic and animal re-
search were so variable that it was not always possible to
disaggregate the data usefully [107].
The Home Office Annual Statistics of Scientific Proce-
dures on Living Animals is the closest form of monitor-
ing of animal research in the UK, but the report does
not document details of expenditure or funding of ani-
mal research. In 2012 it reported that 48 % of animal re-
search was carried out by academia; 27 % by industry;
13 % by public bodies and 9 % by NGO's.
Recommendation (9) RATIONALISE animal research
by carrying out a full economic assessment.
Bias from reductionist-materialism in science
Researchers working with animal models understand that
the resulting data cannot always be relied on for predictive
value and translation to patients. They operate within a
narrow remit embedded in reductionist-materialism, a be-
lief in science which holds that everything can be reduced
down to an observable and controllable material part and
isolated from other neighbouring or related parts with
little or no consequence [108, 109]. An example of how
this can lead to problems is seen in gene research when it
ignores the behaviour and effects of ‘cell intelligence;’ an
oversight that produces misleading data. Findings in
epigenetics explain that local and external environmental
factors can influence and control the behaviour of genes
and must be taken into account.
Since publication of the FDA White Paper in 2004 [11]
there has been little progress in discovering scientifically
sound predictive animal models, despite more than ad-
equate funding and support for the development of new
animal models [12, 13]. Nevertheless, there are pockets of
innovation where researchers are developing tools and
models that may reliably predict the human response:
In the field of CNS drug discovery, Geerts and
colleagues model disease using a 'humanised' approach
with what they call 'computerised biophysically realistic
disease-modelling' while incorporating the issue of
polypharmacy in their methods - something that can
never be achieved in animal models or human trials
[110]. To perfect their in silico models they have made
use of some existing pre-clinical published animal data
(mostly primate) and combined it with human imaging
and genotypic and clinical information. They also pay
attention to quality of life and patient and care-giver
needs when designing research, which they focus on
patient-centred healthcare [111].
At Columbia University Professor Raza has spent the
last 30 years collecting human cells, biopsies and
samples with which she has assembled a tissue
repository supported by a databank of clinical,
pathologic and morphologic data. The repository is
used for research into myelodysplastic syndrome
(MDS) but when Raza applied to the NIH for funding
to validate her human-focused research, which she
describes as "startlingly predictive," the response
was that she should first reproduce the work in mice
[66]. It took over three years to gain funding, and
then only after some of the aims of the research were
dropped to avoid unnecessary and inappropriate
animal studies (private communication with the
author).
Collaborative work by the Wyss Institute at Harvard
University and AstraZeneca is researching innovative
ways of predicting the human response with
'Biologically Inspired Engineering' to create human
organ-on-a-chip technology [112], which they hope
will in the long-term fulfil the search for predictive
models for humans. And transition is in progress
in toxicology testing at the National Center for
Advancing Translational Sciences (NCATS), where
they are developing evidence-based toxicity test
methods [106].
A group of oncology surgeons writing in the American
Journal of Translational Research earlier this year
proposed a number of different methods for improving
the translation of oncology research to patients such as
Phase 0 patient trials (micro-dosing), epidemiological
studies, autopsies, in vitro studies, in silico computer
modelling, silicon and plastic chip technology, and
microfluidic chips [32].
Recommendation (10) REINVENT and support new
ways of looking at pre-clinical research.
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Bias in debate and presentation of animal research
Animal models are promoted by industry as a commod-
ity for drug development, rather than the complex bio-
logical systems that they are. Companies overstate their
value with inflated, obtuse or scientifically unsound ad-
vertisements for commercial gain. Jackson Laboratories,
for example, claim 'Humanised mouse models represent
powerful tools for studying haematopoiesis, inflamma-
tory disease, viral host-pathogen interactions, and are
helping to accelerate the development of novel therapies
in HIV infection and oncology'. JAXmice®, states, 'Be-
cause mice and humans share 95 % of their genes,
mice are an effective and efficient model for human
diseases'. Such statements may be misleading when
advertising animal models with claims that have not
been verified [113]. Mouse and other animal models
may well be involved in many fields of research, but
evidence is still needed to verify their predictive value
for humans.
Investors in biotechnology will be aware that pharma-
ceutical companies usually issue a ‘Safe Harbor’ declar-
ation at the end of their press releases. These refer to
what are termed ‘Forward-Looking Statements’ which
contain claims about the predictive value and subse-
quent monetary value of work carried out. In effect, the
statements provide legal cover for risks and uncertainties
that may arise from investment in companies that make
drugs, medical products or devices to be tested in ani-
mal and clinical trials and then released onto the market.
These statements indicate how human disease is set in
the context of commercial enterprise, with emphasis on
financial reward from sales of drugs.
University and research institutions have been found issu-
ing inflated claims about their own research results in order
to attract maximum media coverage. Press releases fre-
quently contain unsubstantiated declarations about ‘medical
breakthroughs’ and ‘positive results' but without explaining
that the findings may be in the early pre-clinical animal re-
search phase and that have yet to be verified [114].
Recommendation (+) REPRESENT animal research
honestly and with scientific evidence.
Strategy
To support the mission of better science for better
healthcare, the charity SABRE Research UK suggests a
strategy for improving pre-clinical research:
1. Systematic review: a moratorium on animal trials
(in line with calls for a moratorium on efficacy
clinical trials) while a large-scale global programme
of systematic reviews of existing animal studies is
carried out, including systematic reviews of the
value of animal research for the seven leading
causes of death (Western world).
2. Scientific evaluation: a) evaluation of the validation
methods of animal models and in relation to the
higher standards set for the validation methods of
non-animal models and technologies. b) a large-scale
research programme to evaluate the predictive value
of existing animal studies (as set out by van Meer
and colleagues).
3. Inquiry: a full scale inquiry into why
unreliable animal data are accepted by regulatory
authorities while at the same time non-animal
models and technologies with predictive value are
less likely to be adopted.
4. Audit: a full and independent public health audit of
spending on animal research.
5. Apply 10Rs + Recommendations3 [See Additional file 1]
Conclusions
The US pharmaceutical industry takes an average of
15 years to achieve marketing approval for a new drug
[115] and the cost of investment in developing a new
medicine is now estimated at $1.3 billion [116]. Given
that drug development is an expensive and lengthy
process, with many compounds failing for each one that
succeeds and that prescription drugs rank third in the
leading causes of death in the Western world [117], it
will be valuable to conduct an audit to assess the costs
and benefits of animal research and its sustainability.
The proportion of published animal research that has
not been systematically reviewed is hard to quantify, but
the high volume of research output means lack of critical
appraisal is wasteful particularly when funding goes into
research that results in more publications about the lim-
itations of animal models [118]. The way animal re-
search is published tends to spawn new research before
effectively synthesising existing research. Researchers
identify numerous difficulties that emerge during at-
tempts at translating animal data to the clinic [119] and
then assert that 'further research is needed', without first
reviewing what went wrong. This paves the way for the
same researchers and others in the field to produce
more papers on similar, or in some cases virtually identi-
cal research, without adequate review. There is little en-
couragement by funding agencies to critically appraise
research, and little incentive for researchers to consider
that their research path may be unproductive and new
ways of looking at questions might be necessary.
Some clinical researchers are now calling for a return
to real evidence-based medicine in order that a highly
individualised system of healthcare can be delivered to
fulfil the long-awaited promise of personalised medicine.
They say that there is too much research being pro-
duced, and which has overtaken the time needed to
evaluate it. Less but better quality human-centred re-
search is the message [120].
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A proposal to suspend clinical research and appraise
all existing data has recently been suggested [109], but a
moratorium with a full and extensive appraisal of exist-
ing animal research may be more important given that
so few animal studies have been systematically reviewed.
It could be time to stall the output of animal research
and systematically review existing literature to see what
can be learnt before proceeding to carry out more re-
search. The work by Geerts and colleagues demonstrates
this can be a productive approach [110, 111] and it may
help the pharmaceutical industry and academia to learn
from drug failures and avoid repeating the same
mistakes.
The almost limitless repository of heterogeneous ani-
mal studies makes it possible to selectively cite papers
that will support almost any claim made about animal
research. It is important, therefore, that clinical investi-
gators accept responsibility for ensuring that the
animal data they use is scientifically sound before pro-
ceeding with human trials.
Research to determine whether negative results of
animal studies may lead to the abandonment of
research that would be effective for patients needs
prioritisation. SR and scientific evaluation of the
validation methods of animal models is also needed,
so that robust and concordant methods can be devel-
oped, and complete and transparent analysis of the
predictive value of animal studies should be under-
taken without further delay.
The problem of how bias in animal research can falsify
medical research may not reach the understanding of a
wider audience. Many journals remain closed-access,
with valuable content locked behind paywalls when
patients, medical students, healthcare workers, re-
searchers, libraries, policy makers and journalists need
access to medical literature to make informed decisions.
[121, 122] While debate about animal research and
whether it is relevant to human health continues to lack
quality [123], the problem remains that allowing bias in
the research to go unchallenged is unethical for patients
and research participants. If voluntary commitment to
apply the proposed measures cannot be relied on, action
may need to be taken by the public before real improve-
ments are made.
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discovery of the mechanism of protein synthesis. Stud
Hist Philos Biol Biomed Sci. 2002;33:1-28 and Glenman
S. Modeling mechanisms. Stud Hist Philos Biol Biomed
Sci. 2005;36:443-464.
3The 10Rs + Recommendations was circulated in
December 2013 to animal researchers and systematic re-
viewers and at http://sabreresearchuk.wordpress.com/ for
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